Omega-3 Fatty Acid Therapy for Heart Failure Mortality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for symptomatic heart failure, particularly in patients with left ventricular ejection fraction <40%, diabetes, and low total cholesterol, do not effectively reduce mortality or hospitalization for cardiovascular causes over the long term.
Innovation Solution
Administration of a mixture of omega-3 polyunsaturated fatty acids (n-3 PUFA) with a high content of EPA and DHA, between 75% and 95% by weight, for more than 3.5 years, either alone or in combination with other therapeutic agents, to reduce cardiovascular mortality and hospitalization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard therapies (ACE-inhibitors, beta-blockers, diuretics) are administered to patients with symptomatic heart failure, then hemodynamic parameters and symptoms are managed, but long-term mortality and cardiovascular hospitalization rates remain high (10% annual mortality)
Solution Approach 1:
The patent introduces a new therapeutic parameter (n-3 PUFA supplementation) with specific dosing parameters (4g/day of EPA and DHA ethyl esters) to modify the biochemical environment in heart failure patients. This parameter change addresses the limitation of current therapies by adding a biochemical intervention that reduces arrhythmia risk and improves survival, directly targeting the unmet need for improved long-term outcomes
2Reliability
If n-3 PUFA is administered at a dose of 4 g per day for decreasing triglycerides and improving lipoprotein levels, then metabolic parameters are improved, but the specific impact on heart failure mortality and hospitalization was not previously established
Solution Approach 1:
The patent establishes through preliminary clinical trial data that high-dose n-3 PUFA administration (4g/day) produces beneficial effects on mortality and hospitalization in heart failure patients. This preliminary evidence from the Italian Heart Failure Trial provides the foundation for recommending this dosing regimen, showing that the preliminary action of metabolic improvement translates into clinically significant survival benefits
Data Source
Figure 1
Figure 2a
Figure 2b
AI summary
The main object here is the use of omega-3 polyunsaturated fatty acids (as ethyl esters, hereinafter called "n-3 PUFA") as a medicament, either alone or in combination with other therapeutic agents, for reducing mortality for a cardiovascular cause, in particular arrhythmia or for reducing hospitalization for any cause, in particular a cardiovascular cause and for the daily administration to patients with symptomatic heart failure (HF) for more than 3.5 years.